555 related articles for article (PubMed ID: 18407917)
21. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
22. Thymol inhibits Candida albicans biofilm formation and mature biofilm.
Braga PC; Culici M; Alfieri M; Dal Sasso M
Int J Antimicrob Agents; 2008 May; 31(5):472-7. PubMed ID: 18329858
[TBL] [Abstract][Full Text] [Related]
23. Fungal biofilm inhibition by a component naturally produced by Candida albicans yeasts growing as a biofilm.
Cateau E; Berjeaud JM; Rodier MH; Imbert C
Int J Antimicrob Agents; 2008 Feb; 31(2):166-70. PubMed ID: 18160264
[TBL] [Abstract][Full Text] [Related]
24. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
Niimi K; Monk BC; Hirai A; Hatakenaka K; Umeyama T; Lamping E; Maki K; Tanabe K; Kamimura T; Ikeda F; Uehara Y; Kano R; Hasegawa A; Cannon RD; Niimi M
J Antimicrob Chemother; 2010 May; 65(5):842-52. PubMed ID: 20233776
[TBL] [Abstract][Full Text] [Related]
25. Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods.
Cantón E; Pemán J; Hervás D; Espinel-Ingroff A
J Antimicrob Chemother; 2013 Apr; 68(4):864-8. PubMed ID: 23228935
[TBL] [Abstract][Full Text] [Related]
26. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases.
Tobudic S; Lassnigg A; Kratzer C; Graninger W; Presterl E
Mycoses; 2010 May; 53(3):208-14. PubMed ID: 19298353
[TBL] [Abstract][Full Text] [Related]
27. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
[TBL] [Abstract][Full Text] [Related]
28. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.
Maki K; Matsumoto S; Watabe E; Iguchi Y; Tomishima M; Ohki H; Yamada A; Ikeda F; Tawara S; Mutoh S
Microbiol Immunol; 2008 Aug; 52(8):383-91. PubMed ID: 18667037
[TBL] [Abstract][Full Text] [Related]
29. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm.
Raad II; Hachem RY; Hanna HA; Fang X; Jiang Y; Dvorak T; Sherertz RJ; Kontoyiannis DP
Int J Antimicrob Agents; 2008 Dec; 32(6):515-8. PubMed ID: 18783924
[TBL] [Abstract][Full Text] [Related]
30. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms.
Bink A; Kucharíková S; Neirinck B; Vleugels J; Van Dijck P; Cammue BP; Thevissen K
J Infect Dis; 2012 Dec; 206(11):1790-7. PubMed ID: 22984120
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces.
Samaranayake YH; Cheung BP; Parahitiyawa N; Seneviratne CJ; Yau JY; Yeung KW; Samaranayake LP
Arch Oral Biol; 2009 Feb; 54(2):115-26. PubMed ID: 19038377
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
34. Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans.
Bland CM; Thomas S
Ann Pharmacother; 2009 Mar; 43(3):528-31. PubMed ID: 19261955
[TBL] [Abstract][Full Text] [Related]
35. Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms.
Kovács R; Bozó A; Gesztelyi R; Domán M; Kardos G; Nagy F; Tóth Z; Majoros L
Int J Antimicrob Agents; 2016 Apr; 47(4):304-10. PubMed ID: 26968084
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
[TBL] [Abstract][Full Text] [Related]
37. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.
Shuford JA; Rouse MS; Piper KE; Steckelberg JM; Patel R
J Infect Dis; 2006 Sep; 194(5):710-3. PubMed ID: 16897672
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms.
Mukherjee PK; Long L; Kim HG; Ghannoum MA
Int J Antimicrob Agents; 2009 Feb; 33(2):149-53. PubMed ID: 18945596
[TBL] [Abstract][Full Text] [Related]
40. Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin.
Kucharíková S; Tournu H; Lagrou K; Van Dijck P; Bujdáková H
J Med Microbiol; 2011 Sep; 60(Pt 9):1261-1269. PubMed ID: 21566087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
